Indications
Kanuma is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
Composition
- Active substance
- sebelipase alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kanuma
- Active substance
- sebelipase alfa
- ATC code
- A16
- Therapeutic area
- Lipid Metabolism, Inborn Errors
- Marketing authorisation holder
- Alexion Europe SAS
- Status
- Authorised
- EU authorisation
- 28 Aug 2015